 NEW YORK, March 23, 2021 PRNewswire -- Relmada Therapeutics, Inc. Nasdaq: RLMD, a late-stage biotechnology company addressing diseases of the central nervous system CNS, today provided a corporate update and announced financial results for the fourth quarter and full-year ended December 31, 2020. We have achieved significant progress in advancing our lead product candidate, REL-1017, which has the potential to be the first U.S. Food and Drug Administration FDA-approved anti-depressant for adjunctive treatment of major depressive disorder MDD, said Dr. Sergio Traversa, Relmadas Chief Executive Officer. 